HC Wainwright Forecasts Higher Earnings for Biomea Fusion

Biomea Fusion, Inc. (NASDAQ:BMEA - Free Report) - Analysts at HC Wainwright raised their Q2 2025 earnings per share (EPS) estimates for shares of Biomea Fusion in a report released on Monday, June 23rd. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.46) for the quarter, up from their previous forecast of ($0.66). HC Wainwright currently has a "Buy" rating and a $18.00 price objective on the stock. The consensus estimate for Biomea Fusion's current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Biomea Fusion's Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.92) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.14) EPS and FY2028 earnings at ($2.27) EPS.

BMEA has been the topic of several other reports. D. Boral Capital reiterated a "buy" rating and set a $16.00 price objective on shares of Biomea Fusion in a research report on Tuesday. Piper Sandler assumed coverage on Biomea Fusion in a research report on Tuesday, June 3rd. They set an "overweight" rating and a $7.00 price target on the stock. Oppenheimer set a $10.00 price target on Biomea Fusion in a research report on Monday, March 24th. Finally, Barclays cut their price objective on Biomea Fusion from $11.00 to $3.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 2nd. One analyst has rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $21.40.

Biomea Fusion Stock Down 9.0%

Shares of Biomea Fusion stock traded down $0.18 during trading on Thursday, hitting $1.81. 4,503,914 shares of the stock traded hands, compared to its average volume of 1,150,812. The stock has a market cap of $68.00 million, a price-to-earnings ratio of -0.51 and a beta of -0.23. The firm's fifty day moving average is $1.94 and its 200-day moving average is $2.86. Biomea Fusion has a 52 week low of $1.29 and a 52 week high of $13.07.

Biomea Fusion (NASDAQ:BMEA - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.04.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Bayesian Capital Management LP purchased a new position in Biomea Fusion during the fourth quarter valued at $42,000. Wells Fargo & Company MN raised its stake in Biomea Fusion by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 12,914 shares of the company's stock valued at $50,000 after buying an additional 4,399 shares during the last quarter. Intech Investment Management LLC purchased a new position in Biomea Fusion during the fourth quarter valued at $54,000. Maia Wealth LLC purchased a new position in Biomea Fusion during the fourth quarter valued at $62,000. Finally, CWM LLC raised its stake in Biomea Fusion by 8,058.5% during the first quarter. CWM LLC now owns 16,888 shares of the company's stock valued at $36,000 after buying an additional 16,681 shares during the last quarter. Hedge funds and other institutional investors own 96.72% of the company's stock.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.